AN2 Therapeutics Inc. – Material Contracts Watch

from 10-K 6 pages January 29, 2026 Lucy O. Day 2032 Middlefield Road Palo Alto, Ca 94301 Re: Amended and Restated Employment Letter Agreement

from 8-K 19 pages Registration Rights Agreement

from 8-K 41 pages Securities Purchase Agreement

from 10-Q 5 pages Amended and Restated Non-Employee Director Compensation Policy Effective May 22, 2025

from 10-Q 5 pages Amended and Restated Non-Employee Director Compensation Policy Effective November 21, 2024

from 10-K 27 pages Exclusive Patent License Agreement

from 10-K 5 pages Amended and Restated Non-Employee Director Compensation Policy Effective September 27, 2024

from 10-Q 3 pages Amended and Restated Non-Employee Director Compensation Policy Effective March 28, 2024

from 10-K 14 pages The Plan Includes Two Components: A 423 Component and a Non-423 Component. the Company Intends (But Makes No Undertaking or Representation to Maintain) the 423 Component to Qualify as an Employee Stock Purchase Plan. the Provisions of the 423 Component, Accordingly, Will Be Construed in a Manner That Is Consistent With the Requirements of Section 423 of the Code. Except as Otherwise Provided in the Plan or Determined by the Board, the Non-423 Component Will Operate and Be Administered in the Same Manner as the 423 Component. (C) the Company, by Means of the Plan, Seeks to Retain the Services of Such Employees, to Secure and Retain the Services of New Employees, and to Provide Incentives for Such Persons to Exert Maximum Efforts for the Success of the Company and Its Related Corporations. 2. Administration. (A) the Board or the Committee Will Administer the Plan. References Herein to the Board Shall Be Deemed to Refer to the Committee Except Where Context Dictates Otherwise. (B) the Board Will Have the Power, Subject To, and Within the Limitations Of, the Express Provisions of the Plan: (I) to Determine How and When Purchase Rights Will Be Granted and the Provisions of Each Offering (Which Need Not Be Identical)

from 10-K 6 pages AN2 Therapeutics, Inc. Rsu Award Grant Notice

from 10-K 30 pages AN2 Therapeutics, Inc. 2022 Equity Incentive Plan Adopted by the Board of Directors: March 17, 2022 Approved by the Stockholders: March 18, 2022

from 10-K 5 pages April 30, 2021 Paul Eckburg, M.D. Re: Employment Terms Dear Paul: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on April 30, 2021 (The “Start Date”). Position

from 10-K 5 pages November 19, 2019 Kevin M. Krause Re: Employment Terms Dear Kevin: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on November 21, 2019 (The “Start Date”). Position

from 10-Q 5 pages September 19, 2022 Joshua M. Eizen Re: Employment Terms Dear Josh: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment With the Start Date No Later Than September 29, 2022 (The “Start Date”). Position

from S-1 19 pages This Amended and Restated Global Health Agreement (“Global Health Agreement”) Is Entered Into in Connection With the Commitment by Adjuvant Global Health Technology Fund L.P. and Adjuvant Global Health Technology Fund De L.P. (Together, “Adjuvant”) to Purchase and Subscribe for 198,333 Series B Preferred Shares of AN2 Therapeutics, Inc., a Delaware Corporation (The “Company”) at a Price of $35.20404 Per Share (For a Total of $6,999,972.84) (The “Investment”) and Pursuant to Adjuvant’s Prior Subscription of 834,724 Series a Preferred Shares at a Price of $5.99 Per Share (For a Total of $4,999,996.76). Adjuvant Is Making the Investment in Particular Pursuant to the Terms of This Global Health Agreement, the Series B Preferred Stock Purchase Agreement Dated March 5, 2021, the Amended and Restated Investors’ Rights Agreement Dated March 5, 2021 and the Amended and Restated Certificate of Incorporation of the Company Approved by the Stockholders of the Company on March 4, 2021, Each Such Documents as Amended From Time to Time (Collectively, the “Investment Documents”). 1. Background

from S-1 60 pages License Agreement

from S-1 45 pages License Agreement

from S-1 13 pages November 19, 2019 Sanjay Chanda, PH.D. Re: Employment Terms Dear Sanjay: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on or Around November 20, 2019, Subject to the Initial Closing of the Company’s Series a Preferred Stock Financing (The “Start Date”). Position

from S-1 13 pages November 19, 2019 Lucy O. Day Re: Employment Terms Dear Lucy: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on or Around November 20, 2019, Subject to the Initial Closing of the Company’s Series a Preferred Stock Financing (The “Start Date”). Position

from S-1 13 pages November 19, 2019 Eric Easom Re: Employment Terms Dear Eric: AN2 Therapeutics, Inc. (The “Company”) Is Pleased to Offer You Employment Beginning on or Around November 20, 2019, Subject to the Initial Closing of the Company’s Series a Preferred Stock Financing (The “Start Date”). Position